نتایج جستجو برای: botulinum neurotoxin a

تعداد نتایج: 13434741  

Journal: :PLoS Pathogens 2008
Pål Stenmark Jérôme Dupuy Akihiro Imamura Makoto Kiso Raymond C. Stevens

Botulinum neurotoxins have a very high affinity and specificity for their target cells requiring two different co-receptors located on the neuronal cell surface. Different toxin serotypes have different protein receptors; yet, most share a common ganglioside co-receptor, GT1b. We determined the crystal structure of the botulinum neurotoxin serotype A binding domain (residues 873-1297) alone and...

2015
Skadi Kull K. Melanie Schulz Jasmin Weisemann née Strotmeier Sebastian Kirchner Tanja Schreiber Alexander Bollenbach P. Wojtek Dabrowski Andreas Nitsche Suzanne R. Kalb Martin B. Dorner John R. Barr Andreas Rummel Brigitte G. Dorner

Botulism is a severe neurological disease caused by the complex family of botulinum neurotoxins (BoNT). Based on the different serotypes known today, a classification of serotype variants termed subtypes has been proposed according to sequence diversity and immunological properties. However, the relevance of BoNT subtypes is currently not well understood. Here we describe the isolation of a nov...

Journal: :The Journal of biological chemistry 1994
T Nishiki Y Kamata Y Nemoto A Omori T Ito M Takahashi S Kozaki

The protein receptor for Clostridium botulinum type B neurotoxin was purified 340-fold from rat synaptosomes by successive chromatography on DEAE-Sepharose, phenyl-Toyopearl, and heparin-Toyopearl columns. 125I-Labeled neurotoxin bound to lipid vesicles containing the protein receptor and ganglioside GT1b or GD1a. The reconstituted receptor showed the same affinities as the native receptor on s...

Journal: :Applied and environmental microbiology 2010
Clare M Cooksley Ian J Davis Klaus Winzer Weng C Chan Michael W Peck Nigel P Minton

A significant number of genome sequences of Clostridium botulinum and related species have now been determined. In silico analysis of these data revealed the presence of two distinct agr loci (agr-1 and agr-2) in all group I strains, each encoding putative proteins with similarity to AgrB and AgrD of the well-studied Staphylococcus aureus agr quorum sensing system. In S. aureus, a small diffusi...

Journal: :Aesthetic surgery journal 2009
Mitchell S Wortzman Andy Pickett

BACKGROUND Since the first comprehensive description of the physiologic effects of botulism toxicity in the 1820s, specific formulations of botulinum neurotoxin type A (BoNT-A) have been developed. Now, a new botulinum neurotoxin type A formulation (BoNTA-ABO; Dysport [abobotulinumtoxinA]; Medicis Aesthetics, Scottsdale, AZ) has been made available in the United States and these same physiologi...

2003
Michael Barnes

J Rehabil Med Suppl 41, 2003 DOI 10.1080/16501960310010151 Botulinum toxin is a potent neurotoxin produced by the bacterium Clostridium botulinum. There are seven serotypes, all of which block the release of acetylcholine from nerve endings, which gives the compound its theoretical base for reducing spasticity. Initial studies of the use of botulinum toxin in the management of spasticity were p...

2015
Tina I Lam Larry H Stanker Kwangkook Lee Rongsheng Jin Luisa W Cheng

Botulinum neurotoxins (BoNTs) are some of the most poisonous natural toxins. Botulinum neurotoxins associate with neurotoxin-associated proteins (NAPs) forming large complexes that are protected from the harsh environment of the gastrointestinal tract. However, it is still unclear how BoNT complexes as large as 900 kDa traverse the epithelial barrier and what role NAPs play in toxin translocati...

2010
Sarah Adler Gerd Bicker Hans Bigalke Christopher Bishop Jörg Blümel Dirk Dressler Joan Fitzgerald Frank Gessler Heide Heuschen Birgit Kegel Andreas Luch Catherine Milne Andrew Pickett Heidemarie Ratsch Irmela Ruhdel Dorothea Sesardic Martin Stephens Gerhard Stiens Peter D. Thornton René Thürmer Martin Vey Manfred Liebsch

An Expert Meeting on The Current Scientific and Legal Status of Alternative Methods to the LD50 Test for Botulinum Neurotoxin (BoNT) Potency Testing was organised by the Centre for Documentation and Evaluation of Alternatives to Animal Experiments (ZEBET) at the Federal Institute for Risk Assessment (BfR), and took place on 27–28 April 2009, in Berlin, Germany. The goal of ZEBET is to promote p...

Journal: :Medicina oral, patologia oral y cirugia bucal 2010
Burcu Baş Bora Ozan Mehtap Muğlali Nükhet Celebi

Masseter muscle hypertrophy is a rare condition of unknown cause which is important in the differential diagnosis of head and neck masses, located in the cheek. Several treatment options reported for masseter hypertrophy, which range from simple pharmacotherapy to more invasive surgical reduction. Botulinum toxin type A is a powerful neurotoxin which is produced by the anaerobic organism Clostr...

2016
Xiaqing Li Julie A. Coffield Louis S Premkumar

BACKGROUND Botulinum neurotoxins are produced by Clostridium botulinum bacteria. There are eight serologically distinct botulinum neurotoxin isoforms (serotypes A-H). Currently, botulinum neurotoxin serotype A (BoNT⁄A) is commonly used for the treatment of many disorders, such as hyperactive musculoskeletal disorders, dystonia, and pain. However, the effectiveness of BoNT⁄A for pain alleviation...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید